Novartis Ag (NVS) Asset Writedowns and Impairment (2009 - 2015)

Novartis Ag has reported Asset Writedowns and Impairment for 5 years, with the latest figure at -$166.0 million in Q4 2015.

• Quarterly Asset Writedowns and Impairment rose 40.07% year-over-year to -$166.0 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was -$1.5 billion (down 10.61% YoY) and the FY2010 annual result came in at -$911.0 million, down 3403.85% from the prior year.
• Asset Writedowns and Impairment climbed to -$166.0 million in Q4 2015 per NVS's latest filing, from -$277.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at -$106.0 million in Q4 2013 and troughed at -$277.0 million in Q4 2014.
• A 3-year average of -$183.0 million and a median of -$166.0 million in 2015 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2014 and 2015: Asset Writedowns and Impairment plunged 161.32% in 2014, then surged 40.07% in 2015.
• Over 3 years, Asset Writedowns and Impairment stood at -$106.0 million in 2013, then slumped by 161.32% to -$277.0 million in 2014, then soared by 40.07% to -$166.0 million in 2015.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$166.0 million, -$277.0 million, and -$106.0 million for Q4 2015, Q4 2014, and Q4 2013 respectively.